CN102076330A - 替卡格泮钾的固体剂量制剂 - Google Patents

替卡格泮钾的固体剂量制剂 Download PDF

Info

Publication number
CN102076330A
CN102076330A CN2009801252261A CN200980125226A CN102076330A CN 102076330 A CN102076330 A CN 102076330A CN 2009801252261 A CN2009801252261 A CN 2009801252261A CN 200980125226 A CN200980125226 A CN 200980125226A CN 102076330 A CN102076330 A CN 102076330A
Authority
CN
China
Prior art keywords
oxo
potassium
solid dosage
pharmaceutical formulations
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801252261A
Other languages
English (en)
Chinese (zh)
Inventor
M·马哈古尔
张丹
A·J·莫门特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN102076330A publication Critical patent/CN102076330A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2009801252261A 2008-06-30 2009-06-29 替卡格泮钾的固体剂量制剂 Pending CN102076330A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13354208P 2008-06-30 2008-06-30
US61/133542 2008-06-30
PCT/US2009/049009 WO2010002763A1 (en) 2008-06-30 2009-06-29 Solid dosage formulations of telcagepant potassium

Publications (1)

Publication Number Publication Date
CN102076330A true CN102076330A (zh) 2011-05-25

Family

ID=41057505

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801252261A Pending CN102076330A (zh) 2008-06-30 2009-06-29 替卡格泮钾的固体剂量制剂

Country Status (16)

Country Link
US (1) US20100009967A1 (https=)
EP (1) EP2303238A1 (https=)
JP (2) JP2011526909A (https=)
KR (1) KR20110025926A (https=)
CN (1) CN102076330A (https=)
AR (1) AR072395A1 (https=)
AU (1) AU2009267145A1 (https=)
CA (1) CA2728547A1 (https=)
CR (1) CR20110038A (https=)
DO (1) DOP2010000409A (https=)
IL (1) IL209833A0 (https=)
MX (1) MX2010014524A (https=)
RU (1) RU2011103170A (https=)
SV (1) SV2010003774A (https=)
TW (1) TW201004954A (https=)
WO (1) WO2010002763A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125979B2 (en) * 2007-10-25 2015-09-08 Proteus Digital Health, Inc. Fluid transfer port information system
AU2009212514A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Prodrugs of CGRP receptor antagonist
WO2017001434A1 (en) * 2015-06-29 2017-01-05 Galderma Research & Development Cgrp receptor antagonist compounds for topical treatment of skin disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
WO1998040069A2 (en) * 1997-03-13 1998-09-17 Hexal Ag Stabilization of acid sensitive benzimidazoles with amino acid/cyclodextrin combinations
US6174548B1 (en) * 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
AU2007238896A1 (en) * 2006-04-10 2007-10-25 Merck Sharp & Dohme Corp. CGRP antagonist salt
EP2063708A2 (en) * 2006-09-08 2009-06-03 Merck & Co., Inc. Liquid pharmaceutical formulations for oral administration of a cgrp antagonist

Also Published As

Publication number Publication date
RU2011103170A (ru) 2012-08-10
CA2728547A1 (en) 2010-01-07
US20100009967A1 (en) 2010-01-14
TW201004954A (en) 2010-02-01
EP2303238A1 (en) 2011-04-06
AR072395A1 (es) 2010-08-25
MX2010014524A (es) 2011-02-24
SV2010003774A (es) 2011-03-23
CR20110038A (es) 2011-03-16
AU2009267145A1 (en) 2010-01-07
IL209833A0 (en) 2011-02-28
KR20110025926A (ko) 2011-03-14
DOP2010000409A (es) 2011-02-15
JP2011246478A (ja) 2011-12-08
WO2010002763A1 (en) 2010-01-07
JP2011526909A (ja) 2011-10-20

Similar Documents

Publication Publication Date Title
KR101005716B1 (ko) ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태
EP3964503B1 (en) A crystalline form of a magl inhibitor
CN101594863B (zh) 具有改进稳定性的涂膜制剂
EP2364142B1 (en) Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
EP4487908A2 (en) Methods of treating crohn's disease and ulcerative colitis
HU230161B1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
WO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
CN113925833A (zh) 包含酪氨酸蛋白激酶抑制剂的剂型组合物
KR20050042154A (ko) 통증의 치료에 사용하기 위한 알파-2-델타 리간드와 ｐｄｅｖ 억제제의 상승작용 조합물
EP3463312A1 (en) Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
WO2004054574A1 (ja) 経口固形医薬
CN102076330A (zh) 替卡格泮钾的固体剂量制剂
US10085991B2 (en) Formulation inhibiting effects of low acid environment
CN109157527B (zh) 一种厄贝沙坦胶囊及其制备方法
EP2544690A2 (en) Arylvinylazacycloalkane compounds for constipation
CA3218977A1 (en) A plurality of tasquinimod particles and use thereof
KR100912196B1 (ko) Ｌｔｂ4 길항제를 함유하는 약제학적 제형
HK40107035A (en) A plurality of tasquinimod particles and use thereof
HK40107035B (en) A plurality of tasquinimod particles and use thereof
HK40059863A (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
HK40069310B (en) A crystalline form of a magl inhibitor
HK40004728A (en) Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto
KR101125453B1 (ko) 엘-트립토판의 가용화 조성물 및 이를 이용한 제제
HK1258699B (en) Dosage form compositions comprising an inhibitor of bruton's tyrosine kinase
HK1161843A (en) Compositions of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110525